Natixis Fate Therapeutics Inc Transaction History

Natixis

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$4.24 - $11.12 $712 - $1,868	-168 Reduced 5.85%	2,703 $15,000
Q4 2022 Feb 24, 2023	BUY	$9.86 - $23.83 $28,308 - $68,415	2,871 New	2,871 $28,000
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $171,349 - $276,755	-2,891 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$67.25 - $92.52 $194,419 - $267,475	2,891 New	2,891 $251,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.